<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889343</url>
  </required_header>
  <id_info>
    <org_study_id>AIO KRK 0307</org_study_id>
    <nct_id>NCT00889343</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer</brief_title>
  <acronym>FOSCO</acronym>
  <official_title>A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sorafenib in combination with chemotherapy
      has a positive effect on time to progression of the tumor or death for the treatment of large
      bowel cancer that has already progressed during a first chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with metastatic CRC who received a first-line therapy with an Oxaliplatin- or
      Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab and had a progression
      subsequently, are eligible for this study. Patients will be randomized to receive
      chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib 400 mg bid or chemotherapy + placebo. Patients
      who have received an Oxaliplatin based Fluoropyrimidine containing regimen in first-line will
      obtain FOLFIRI during this study. Patients who have received an Irinotecan based
      Fluoropyrimidine containing regimen in first-line will obtain FOLFOX6.

      Primary objective of the study is to compare the Progression-free-survival (PFS) between
      patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo</measure>
    <time_frame>6 to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>6 to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>signature of informed consent until 30 days after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin or Irinotecan</intervention_name>
    <description>Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>400 mg/m2 intravenous infusion on day 1 of a 14-days cycle</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  ECOG Performance Status of 0 to 2

          -  Life expectancy of at least 12 weeks.

          -  Subjects with at least one uni-dimensional (RECIST) measurable lesion of metastatic
             colorectal carcinoma after first-line chemotherapy with an Oxaliplatin- or Irinotecan
             based Fluoropyrimidine containing regimen ± bevacizumab and had a progression
             subsequently. Lesions must be measured by CT-scan or MRI.

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

          -  Hemoglobin &gt; 9.0 g/dl

          -  Absolute neutrophil count (ANC) &gt;1,500/mm3

          -  Platelet count 100,000/μl Total bilirubin &lt; 1.5 times the upper limit of normal

          -  ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients
             with liver involvement of their cancer)

          -  Alkaline phosphatase &lt; 4 x upper limit of normal

          -  PT-INR/PTT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically
             anticoagulated with an agent such as coumadin or heparin will be allowed to
             participate provided that no prior evidence of underlying abnormality in these
             parameters exists.]

          -  Serum creatinine &lt; 1.5 x upper limit of normal

          -  Signed and dated informed consent before the start of specific protocol procedures

        Exclusion Criteria:

          -  History of cardiac disease: congestive heart failure &gt;NYHA class 2; active CAD (MI
             more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring
             anti-arrythmic therapy (beta blockers or digoxin are permitted) or uncontrolled
             hypertension

          -  History of HIV infection or chronic hepatitis B or C

          -  Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0)

          -  Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months
             from definitive therapy, has a negative imaging study within 4 weeks of study entry
             and is clinically stable with respect to the tumor at the time of study entry)

          -  Patients with seizure disorder requiring medication (such as steroids or
             anti-epileptics)

          -  History of organ allograft

          -  Patients with evidence or history of bleeding diathesis

          -  Patients undergoing renal dialysis

          -  Known deficit in Dihydropyrimidine Deshydrogenase (DPD)

          -  Contraindications for the use of atropine in patients receiving FOLFIRI

          -  Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively
             treated &gt; 3 years prior to study entry.

          -  Peripheral sensory neuropathy &gt; CTC grade 2

          -  Chronic inflammatory bowel disease; ileus; genetic fructose intolerance

          -  Pregnant or breast-feeding patients.

          -  Women of childbearing potential must have a negative pregnancy test performed within 7
             days before the start of treatment. Fertile women and men (&lt;2 years after last
             menstruation in women) must use effective means of contraception (intrauterine
             contraceptive device, contraceptive implants, injectables (hormonal depot),
             transdermal hormonal contraception (contraceptive patch), sexual abstinence or
             vasectomised partner) during treatment and for at least 6 months after last
             administration of medication.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient‟s participation in the study or evaluation of the study results

          -  Any condition that is unstable or could jeopardize the safety of the patient and their
             compliance in the study 18. Patients unable to swallow oral medications.

          -  Any other anticancer chemotherapy or immunotherapy during the study or within 4 weeks
             of study entry.

          -  Radiotherapy during study or within 3 weeks of start of study drug. (Palliative
             radiotherapy will be allowed). Major surgery within 4 weeks of start of study

          -  Autologous bone marrow transplant or stem cell rescue within 4 months prior to study
             treatment

          -  Use of biologic response modifiers, such as G-CSF, within 3 week of study entry.
             [G-CSF and other hematopoietic growth factors may be used in the management of acute
             toxicity such as febrile neutropenia when clinically indicated or at the discretion of
             the investigator, however, they may not be substituted for a required dose reduction.]
             [Patients taking chronic erythropoietin are permitted provided no dose adjustment is
             undertaken within 2 months prior to the study or during the study]

          -  Investigational drug therapy outside of this trial during or within 4 weeks of study
             entry

          -  Prior exposure to the study drug.

          -  Any St. John´s wort containing remedy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Höhler, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum am Siloah St. Trudpert Klinikum</name>
      <address>
        <city>Pforzheim</city>
        <state>Baden-Würtemberg</state>
        <zip>75179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostalb-Klinikum Aalen, Medizinische Klinik 1</name>
      <address>
        <city>Aalen</city>
        <state>Baden-Württemberg</state>
        <zip>73428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Esslingen gGmbH, Klinik Nürtingen, Medizinische Klinik I</name>
      <address>
        <city>Nürtingen</city>
        <state>Baden-Württemberg</state>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Württemberg</state>
        <zip>88214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. U. Banhardt, Dr. med. T. Fietz</name>
      <address>
        <city>Singen</city>
        <state>Baden-Württemberg</state>
        <zip>78224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Zentrum für Innere Medizin, Klinik für Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis Dres. Wilke und Wagner</name>
      <address>
        <city>Fürth</city>
        <state>Bayern</state>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologischonkologische Schwerpunktpraxis</name>
      <address>
        <city>Herrsching</city>
        <state>Bayern</state>
        <zip>82211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologie Onkologie Tagesklinik Landshut</name>
      <address>
        <city>Landshut</city>
        <state>Bayern</state>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Schwerpunktpraxis Prof. Salat / Dr. Stoetzer / Prof. Hiller</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus, Medizinische Klinik II</name>
      <address>
        <city>Schweinfurt</city>
        <state>Bayern</state>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Traunstein -Trostberg GmbH , Innere Medizin/ Hämatologie und Onkologie</name>
      <address>
        <city>Trostberg</city>
        <state>Bayern</state>
        <zip>83308</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt, Medizinische Klinik V</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Frankfurt a.M. - Höchst, Klinik für Innere Medizin Abt. 3</name>
      <address>
        <city>Frankfurt a.M.</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitanus GmbH</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda, Tumorklinik</name>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxisgemeinschaft Dres. Siehl, Söling und Prof. Hirschmann</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität, Klinikum Marburg, Klinik für Innere Medizin mit SP Hämatologie und Onkologie</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahn-Dill-Kliniken GmbH, Darmzentrum</name>
      <address>
        <city>Wetzlar</city>
        <state>Hessen</state>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock, Klinik für Innere Medizin</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wissenschaftskontor Nord GmbH und Co KG</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediProjekt, Gesellschaft für Medizinstatistik und Projektentwicklung</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Siloah, Medizinische Klinik III</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <state>Niedersachsen</state>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologie u. Internistische Onkologie</name>
      <address>
        <city>Lehrte</city>
        <state>Niedersachsen</state>
        <zip>31275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Schwerpunktpraxis Northeim</name>
      <address>
        <city>Northeim</city>
        <state>Niedersachsen</state>
        <zip>37154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen-Kliniken, Marienhospital Osnabrück GmbH,</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus Rotenburg (Wümme) gGmbH, I. Chirurgische Klinik</name>
      <address>
        <city>Rotenburg (Wümme)</city>
        <state>Niedersachsen</state>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft Dr. Hancken und Partner, Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Stade</city>
        <state>Niedersachsen</state>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik-Knappschaftskrankenhaus, Medizinische Klinik</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz-Krankenhaus, Medizinische Klinik I</name>
      <address>
        <city>Datteln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital, Klinik für Hämatologie / Onkologie</name>
      <address>
        <city>Eschweiler</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologisches Gemeinschaftspraxis</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus Hagen gem. GmbH, Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Hagen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie am Sachsenring</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50677</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen gGmbH, Medizinische Klinik III</name>
      <address>
        <city>Leverkusen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis und Tagesklinik für Internistische Onkologie und Hämatologie</name>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosperhospital Recklinghausen, Medizinische Klinik I</name>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Wuppertal , Medizinische Klinik I</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH, Innere Medizin I</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken des Saarlandes, Innere Medizin I</name>
      <address>
        <city>Homburg / Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Praxis Dr. med. Peter Schmidt</name>
      <address>
        <city>Neunkirchen</city>
        <state>Saarland</state>
        <zip>66821</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dessau, Klinik für Innere Medizin</name>
      <address>
        <city>Dessau</city>
        <state>Sachsen-Anhalt</state>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft Dr. med. Thomas Göhler und Steffen Dörfel</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis &amp; Tagesklinik</name>
      <address>
        <city>Neutstadt/Sachsen</city>
        <state>Sachsen</state>
        <zip>01844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Ebert-Krankenhaus Neumünster, Klinik für Hämatologie, Onkologie und Nephrologie</name>
      <address>
        <city>Neumünster</city>
        <state>Schleswig-Holstein</state>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eps-early phase solution GmbH</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophien- und Hufeland-Klinikum gGmbH, Klinik für Innere Medizin II</name>
      <address>
        <city>Weimar</city>
        <state>Thüringen</state>
        <zip>99425</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie-Krankenhaus gGmbH, Medizinische Klinik II</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ für Innere Medizin in Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20248</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>Arbeitsgemeinschaft der internistischen Onkologie</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Second-line therapy of metastatic colorectal cancer</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>palliative therapy</keyword>
  <keyword>after progression of firstline therapy with an Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

